A 28-year-old woman with HIV (CD4 220 cells/µL) on first-line ART (TDF/FTC/EFV) for 6 months presents with fever, headache, and neck stiffness. CSF analysis shows: glucose 35 mg/dL (serum 100), protein 180 mg/dL, WBC 85 (60% lymphocytes), India ink stain negative, bacterial culture negative. Which of the following is NOT a recognized feature or management principle of her presumed diagnosis?

Explanation

## Cryptococcal Meningitis in Advanced HIV ### Clinical Presentation & Diagnosis **Key Point:** The CSF findings (low glucose, elevated protein, lymphocytic pleocytosis, negative India ink in ~10% of cases, negative bacterial culture) are classic for cryptococcal meningitis (CM). The diagnosis is confirmed by CSF cryptococcal antigen (CrAg) or culture. ### Induction Therapy: Amphotericin B vs. Fluconazole | Parameter | Amphotericin B Deoxycholate | Liposomal Amphotericin B | Fluconazole (High-Dose) | |---|---|---|---| | **Role in CM** | Gold standard for induction | Preferred if available (less nephrotoxicity) | Consolidation/maintenance, NOT induction | | **Mortality (induction)** | ~30% at 2 weeks | ~25% at 2 weeks | ~50% at 2 weeks (inferior) | | **Dosing** | 0.7–1 mg/kg/day IV | 3–6 mg/kg/day IV | 800–1200 mg/day PO (high-dose) | | **Flucytosine addition** | Yes (synergistic) | Yes (synergistic) | Not applicable | | **Duration** | 2 weeks (induction) | 2 weeks (induction) | 8–10 weeks (consolidation) | | **Nephrotoxicity** | High (monitor Cr, K, Mg) | Lower | Minimal | ### Why Option 3 Is Incorrect **High-Yield:** Fluconazole monotherapy at any dose is **NOT** recommended as first-line induction therapy for cryptococcal meningitis. This is a critical exam trap. **Clinical Pearl:** The 2023 WHO and CDC guidelines are unambiguous: amphotericin B (conventional or liposomal) + flucytosine is the gold standard induction regimen. Fluconazole is relegated to: - **Consolidation phase** (weeks 2–10) after initial amphotericin B induction. - **Maintenance therapy** (long-term suppression) once CD4 recovers > 100 cells/µL on ART. Fluconazole monotherapy has been shown in RCTs to have **inferior outcomes** (~50% mortality) compared to amphotericin B (~30% mortality) in the first 2 weeks of treatment. Even in resource-limited settings where amphotericin B is unavailable, the recommendation is to use fluconazole as a bridge therapy, not as equivalent induction. ### Why Options 1, 2, and 4 Are Correct - **Option 1:** Correct. Amphotericin B deoxycholate 0.7–1 mg/kg/day IV ± flucytosine is the induction standard. Flucytosine (100 mg/kg/day in 4 doses) enhances fungicidal activity and reduces mortality. - **Option 2:** Correct. Elevated intracranial pressure (ICP) from cryptococcal antigen and inflammatory response is a major driver of morbidity and mortality. Serial therapeutic lumbar punctures (to reduce CSF opening pressure) or ventriculostomy placement are evidence-based interventions to prevent herniation and improve outcomes. - **Option 4:** Correct. IRIS can occur 1–4 weeks after ART initiation in patients with very low CD4 counts. Paradoxical worsening of meningitis symptoms despite negative repeat CSF cultures and rising CD4 count is a hallmark of CM-IRIS. Management includes continuation of ART and anti-fungal therapy, with corticosteroids considered in severe cases. **Warning:** Do not confuse fluconazole's role in consolidation/maintenance with its role in induction. Many students mistakenly think high-dose fluconazole can replace amphotericin B because it achieves good CSF penetration — this is a dangerous misconception.